Denali Therapeutics (DNLI) Peer Comparison

$18.68

$-0.25 (-1.32%)

As on 21-Oct-2026 16:00EDT

Market cap

$2,815 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

--

P/B Ratio

3.9

Div. Yield

0 %

Edit

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	2,815	17,263	14,822	15,419	13,829
Revenue ($ Mln)	4	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-511.45	491.50	755.85	860.62	413.60
Net Margin (%)	-14,191.20	17.67	71.69	35.33	24.86
RoE (%)	-55.32	110.09	--	42.98	430.03
Price to Earnings	--	36.32	17.26	19.63	35.63
Price-To-Book	3.92	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	3.60	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	107.75	1,982.07	103.47	85.67	292.42
Gross Profit	-11.18	760.62	588.53	2,236.43	1,167.84
Operating Expenses	540.50	216.81	841.45	1,378.74	440.53
Operating Profit (EBIT)	-542.70	583.40	109.45	971.51	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-511.35	598.92	101.11	1,035.47	583.34
Provision for Tax	0.10	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-511.45	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	835.18	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	232.69	187.89	384.48	288.55	2,089.43
Current Liabilities	90.08	1,435.43	464.70	361.93	344.44
Total Liabilities	1,144.85	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	404.03	1,006.90	895.24	1,243.41	1,644.38
Current Assets	753.93	1,050.29	1,389.84	1,250.82	933.02
Total Assets	1,144.85	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	27.51	144.11	449.89	165.93	2,146.65
Net Current Assets	663.84	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-412.60	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	255.28	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	189.22	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-44.02	57.43	-30.01	32.82	15.61
ROE (%)	-55.32	110.09	163.18	42.98	430.03
ROA (%)	-40.83	15.64	31.68	29.32	16.19
EBIT Margin (%)	-14,188.37	21.13	5.73	41.82	36.28
Net Margin (%)	-14,191.20	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	24.67	114.85	9.23	41.15
EBIT Growth (%)	-6.76	18.70	136.39	29.37	-14.99
Net Profit Growth (%)	-6.77	17.50	378.76	42.89	-25.78
EPS Growth (%)	-1.07	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-25.57	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-5.65	36.06	-59.76	15.79	24.99
Price / Book Value	2.86	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-4.15	27.88	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.00	0.06	0.05	0.00	1.46
Current Ratio	8.37	0.73	2.99	3.46	2.71
Quick Ratio	8.32	0.73	2.32	3.38	2.31
Interest Coverage	--	--	1.62	--	29.73

Operating Efficiency Ratios

	Denali Therapeutics (DNLI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	108.96	15.88	21.25	13.74	27.40
Asset Turnover	0.00	0.89	0.44	0.83	0.65
Receivable days	--	50.42	85.52	43.48	98.04
Inventory Days	--	--	1,056.70	96.17	254.12
Payable days	236.25	6.26	331.01	147.97	24.86
Cash Conversion Cycle	--	--	811.21	-8.32	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly